Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmv Capital Regulatory News (EMVC)

Share Price Information for Emv Capital (EMVC)

Share Price is delayed by 15 minutes
Get Live Data
49.00    0.00 (0.00%)
Bid:
48.00
Ask:
50.00
Spread: 2.00 (4.167%)
Market Cap: £13.70m
EMVC Live PriceLast checked at - London Stock Exchange

Intraday Emv Capital Share Chart

Portfolio Update

12 Feb 2026 07:00

RNS Number : 6833S
EMV Capital PLC
12 February 2026
 

For announcement on Reach: 12 February 2026

 

EMV Capital plc

 

("EMVC" or the "Company")

 

Portfolio Update

 

As part of its ongoing investor engagement programme, EMV Capital plc (AIM: EMVC), the deep tech and life sciences VC investment group, is pleased to announce that it will host a virtual Meet the Portfolio event on 26 February 2026 at 02.00 p.m. The session will provide investors with greater insight into two of its portfolio companies, Vortex and DName-iT.

 

Virtual Meet the Portfolio - Vortex and DName-iT

 

The online event will take place via the Investor Meet Company platform and will be hosted by Dr Ilian Iliev, CEO of EMV Capital plc, who will be joined by:

· The Managing Director of Vortex, a leader in liquid biopsy technologies for precision oncology; and

· The CEO of DName-iT, a MedTech company applying its patented DNA barcoding method to develop a platform for labelling patients' specimens that are analysed with Next Generation Sequencing.

This presentation is open to all interested parties. Anyone can sign up for free and join the live presentation via:

https://www.investormeetcompany.com/emv-capital-plc/register-investor

Those who already follow the Company on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 25 February 2026 at 09:00 a.m., or at any time during the live presentation.

In accordance with UK Market Abuse Regulation (UK MAR), no inside information will be disclosed during the event.

 

-Ends- 

 

For more information, please contact:

 

 

EMV Capital plc

via Rosewood

 

Ilian Iliev, CEO

 

 

 

Panmure Liberum Limited (NOMAD and Broker)

+44 (0)20 7886 2500

 

Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)

 

 

Rupert Dearden (Corporate Broking)

 

 

 

Rosewood (Financial PR)

+44 (0)20 7653 8702

John West / Llewellyn Angus / Lily Pearce

 

 

About EMV Capital plc (EMVC)

 

EMV Capital plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies.

With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future; EMV Capital invests in, manages and strengthens early-stage IP-rich companies.

EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:

· capital-efficient investments through Group balance sheet;

· fund management of the Evergreen EIS and Martlet Capital Funds;

· syndicated investments leveraging its network of third-party investors.

EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.

Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

www.emvcapital.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUAVORNOUUAUR
12
Date   Source Headline
22nd May 202612:38 pmRNSPosting of Annual Report and Notice of AGM
21st May 20267:00 amRNS-RAMR Bio: Commercial Update
19th May 20267:01 amRNSFinal Results for the year ended 31 December 2025
19th May 20267:00 amRNSPhantom Carried Interest Scheme
14th May 20267:00 amRNSNotice of Final Results
24th Feb 202612:38 pmRNSTR-1
12th Feb 20267:00 amRNS-RPortfolio Update
2nd Feb 20267:00 amRNSTrading and Portfolio Update
8th Jan 20267:00 amRNSPDMR Dealing
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
19th Dec 20257:00 amRNSDirector/PDMR Dealing
19th Dec 20257:00 amRNSDirector/PDMR Dealing
10th Dec 20257:00 amRNS-RWanda Health: Fundraising and Business Update
8th Dec 20257:00 amRNSShare Issue, PDMR Dealings & Total Voting Rights
4th Dec 20257:00 amRNSTR-1
24th Nov 20257:00 amRNSExpansion of Senior Finance Leadership Team
20th Nov 20257:00 amRNS-RPortfolio Update
30th Sep 20257:00 amRNSInterim Results and Investor Presentation
22nd Sep 20257:00 amRNSAsset Purchase Agreement with Destiny Pharma
18th Sep 20257:00 amRNSNotice of Interim Results
30th Jun 202512:22 pmRNSResult of AGM
30th Jun 20257:00 amRNSOffice move and Related Party Transaction
27th Jun 20257:00 amRNSQ-Bot Limited Fundraising
10th Jun 20251:28 pmRNSTR-1
6th Jun 20253:12 pmRNSNotice of AGM and Annual Report & Accounts
4th Jun 20252:34 pmRNSDirector/PDMR Shareholding
4th Jun 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
14th May 20254:02 pmRNSPDS: Q1 Results and Clinical and Corporate Update
9th May 202510:30 amRNSTR-1
27th Mar 20254:46 pmRNSPDS: Q4 Results and Clinical Programs Update
7th Mar 20254:26 pmRNSPDS: VERSATILE-003 Phase 3 Clinical Trial
27th Feb 20254:30 pmRNSPDS: up to $22mn Registered Direct Offering
5th Feb 20253:24 pmRNSPDS Biotech reaffirms guidance for clinical trial
3rd Feb 20257:00 amRNSProAxsis: Status Update and Proposed Fundraise
6th Jan 20254:42 pmRNSTR-1
31st Dec 20247:05 amRNSGrant of Share Options
31st Dec 20247:00 amRNSQ-Bot Fundraising
12th Dec 20244:49 pmRNSTR-1
9th Dec 20247:00 amRNSWanda Health Fundraising
5th Dec 20247:00 amRNSClose of Fundraising and Result of Retail Offer
3rd Dec 20241:24 pmRNSResult of Subscription
3rd Dec 20247:05 amRNSWRAP Retail Offer
3rd Dec 20247:00 amRNSProposed Subscription and Retail Offer; Update
14th Nov 20243:59 pmRNSReplacement RNS: PDS: Update, 3rd Quarter Results
14th Nov 20243:23 pmRNSPDS: Clinical Programs Update, 3rd Quarter Results
8th Oct 20247:00 amRNSDirector/PDMR Shareholding
3rd Oct 20247:00 amRNSDirector/PDMR Shareholding
2nd Oct 20244:38 pmRNSPDS: 36-Month Overall Survival Rate announcement
30th Sep 20247:00 amRNSInterim Results
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.